Fleming, D R <br/><br/>
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.  [electronic resource] 

 -  American journal of clinical oncology  Aug 2000 
 - 349-52 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0277-3732 
<br/><br/><label>Standard No.: </label>10.1097/00000421-200008000-00007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Colonic Neoplasms--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Diarrhea--chemically induced<br/>Esophageal Neoplasms--drug therapy<br/>Exanthema--chemically induced<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Nausea--chemically induced<br/>Neoplasm Staging<br/>Neoplasms, Unknown Primary--drug therapy<br/>Neutropenia--chemically induced<br/>Paclitaxel--administration & dosage<br/>Pancreatic Neoplasms--drug therapy<br/>Paresthesia--chemically induced<br/>Urinary Bladder Neoplasms--drug therapy<br/>Vomiting--chemically induced<br/>Gemcitabine